Your browser doesn't support javascript.
loading
Identification of a pharmacological approach to reduce ACE2 expression and development of an in vitro COVID-19 viral entry model.
Endo, Yukinori; Hickerson, Brady T; Ilyushina, Natalia A; Mohan, Nishant; Peng, Hanjing; Takeda, Kazuyo; Donnelly, Raymond P; Wu, Wen Jin.
Afiliación
  • Endo Y; Division of Biotechnology Review and Research 1 (DBRR1), Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
  • Hickerson BT; Division of Biotechnology Review and Research 2 (DBRR2), Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
  • Ilyushina NA; Division of Biotechnology Review and Research 2 (DBRR2), Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
  • Mohan N; Division of Biotechnology Review and Research 1 (DBRR1), Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
  • Peng H; Division of Biotechnology Review and Research 1 (DBRR1), Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
  • Takeda K; Microscopy and Imaging Core Facility, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
  • Donnelly RP; Division of Biotechnology Review and Research 2 (DBRR2), Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
  • Wu WJ; Division of Biotechnology Review and Research 1 (DBRR1), Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
J Virus Erad ; 8(4): 100307, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36514715
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: J Virus Erad Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: J Virus Erad Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos